GRFS News & Events

Grifols announced the U.S. launch of its new fibrinogen concentrate. Approved by the FDA in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including hypo- or afibrinogenemia, Fesilty is now available in the U.S. Fesilty is not indicated for dysfibrinogenemia.

Grifols says Q1 results support FY26 guidance

Reports Q1 total revenue EUR 1.7B, up 3.3% y/y cc. Group profit increased to EUR 73M in the first quarter, up 21.9% year-on-year. Nacho Abia, CEO of Grifols, said: "We started the year delivering performance in line with our expectations and reassured that we are on track to achieve our guidance for the full-year 2026 as we continue to build momentum over the course of the year. These results were achieved in a complex geopolitical and macroeconomic environment, marked by persistent uncertainties. In this context, these results underscore both the resilience of our business and the strength of our underlying fundamentals."